Veterinary Anesthesia Market Size

Veterinary Anesthesia Market Analysis

The veterinary anesthesia market is expected to register aCAGR of 6.5% during the forecast period.

• The COVID-19 pandemic impacted the veterinary anesthesia market owing to the disruptions in the veterinary medical devices supply chain and cancellations of veterinary surgical procedures in several countries, primarily due to the temporary lockdowns of manufacturing sites, export bans, and increased demand for medicine for the treatment of COVID-19.
• For instance, according to an article published in February 2021, the demand for veterinary services and visits to pet clinics reduced in Mexico during the COVID-19 pandemic, thus impacting the growth of the veterinary anesthesia market. However, the market recovered since the restrictions were lifted and pet clinic services resumed.
• In addition, the rising chronic diseases associated with surgical procedures and technological advancements in veterinary anesthesia are actively affecting the growth of the studied market.
• The recent years have observed a significant rise in the prevalence of veterinary chronic diseases, such as arthritis, chronic kidney disease, hepatitis, skin allergies (atopy), diabetes mellitus, Cushing's and Addison's disease, inflammatory bowel disease, hyperthyroidism (cats) and hypothyroidism (dogs), and many others. Hence, with the high prevalence of these diseases, the number of surgical procedures is expected to rise during the forecast period.
• According to the data reported by Frontiers of Veterinary Science, the prevalence of canine obesity and obesity-related metabolic dysfunction (ORMD), such as hypertension and fasting hypertriglyceridemia/hypercholesterolemia, was reported to be 40.9% and 20.4%, respectively, in Spain in 2021. The high prevalence of canine obesity is expected to increase the surgical procedures requiring anesthesia, thereby boosting market growth.
• Furthermore, an article published in the Journal of Animal Science in July 2021 reported that osteoarthritis (OA) affects about 20% of all adult dogs and over 90% of dogs above five years of age in North America every year. The high burden of the disease requires the use of anesthesia during surgical treatment, thereby propelling the market growth.
• The strategic initiatives adopted by key market players, such as product launches, approvals, and partnerships, are driving the market growth. For instance, in April 2021, Shenzhen Mindray Animal Medical Technology Co., Ltd. launched its new veterinary anesthesia device called Veta 5 or Veta 3. The product launches are anticipated to propel the market growth.
• However, the high cost of anesthesia machines will likely impede the market growth.